Jonathan Levy

645 total citations · 1 hit paper
9 papers, 397 citations indexed

About

Jonathan Levy is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Statistics and Probability. According to data from OpenAlex, Jonathan Levy has authored 9 papers receiving a total of 397 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 3 papers in Statistics and Probability. Recurrent topics in Jonathan Levy's work include Advanced Causal Inference Techniques (3 papers), Colorectal Cancer Treatments and Studies (3 papers) and Peptidase Inhibition and Analysis (2 papers). Jonathan Levy is often cited by papers focused on Advanced Causal Inference Techniques (3 papers), Colorectal Cancer Treatments and Studies (3 papers) and Peptidase Inhibition and Analysis (2 papers). Jonathan Levy collaborates with scholars based in United States, United Kingdom and Australia. Jonathan Levy's co-authors include Funda Meric‐Bernstam, John D. Hainsworth, Howard A. Burris, Razelle Kurzrock, Charles Swanton, Claire F. Friedman, Christopher J. Sweeney, Katja Schulze, Arisha Patel and David R. Spigel and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Jonathan Levy

9 papers receiving 391 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

2021 251 citations Milind Javle, Mitesh J. Borad et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Jonathan Levy

Since Specialization

Citations

This map shows the geographic impact of Jonathan Levy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Levy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Levy more than expected).

Fields of papers citing papers by Jonathan Levy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Levy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Levy. The network helps show where Jonathan Levy may publish in the future.

Co-authorship network of co-authors of Jonathan Levy

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Levy. A scholar is included among the top collaborators of Jonathan Levy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Levy. Jonathan Levy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2–Altered Advanced Solid Tumors 2023 ·Journal of Clinical Oncology ·Christopher J. Sweeney, John D. Hainsworth, Ron Bose, Howard A. Burris, Razelle Kurzrock, Charles Swanton, Claire F. Friedman, David R. Spigel, Tania Szado, Katja Schulze, Richard Price, (unknown), (unknown), Jonathan Levy, Yong Wang, Wei Yu, Funda Meric‐Bernstam	35
2	A fundamental measure of treatment effect heterogeneity 2021 ·SHILAP Revista de lepidopterología ·Jonathan Levy, Mark van der Laan, Alan Hubbard, Romain Pirracchio	7
3	Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study 2021 ·Cancer Discovery ·Claire F. Friedman, John D. Hainsworth, Razelle Kurzrock, David R. Spigel, Howard A. Burris, Christopher J. Sweeney, Funda Meric‐Bernstam, Yong Wang, Jonathan Levy, Jessica M. Grindheim, David S. Shames, Katja Schulze, Arisha Patel, Charles Swanton	56
4	Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study breakdown → 2021 ·The Lancet Oncology ·Milind Javle, Mitesh J. Borad, Nilofer S. Azad, Razelle Kurzrock, Ghassan K. Abou‐Alfa, Ben George, John D. Hainsworth, Funda Meric‐Bernstam, Charles Swanton, Christopher J. Sweeney, Claire F. Friedman, Ron Bose, David R. Spigel, Yong Wang, Jonathan Levy, Katja Schulze, Vaikunth Cuchelkar, Arisha Patel, Howard A. Burris	251
5	MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors. 2021 ·Journal of Clinical Oncology ·Funda Meric‐Bernstam, John D. Hainsworth, Ron Bose, Howard A. Burris, Claire F. Friedman, Razelle Kurzrock, Charles Swanton, Yong Wang, Jonathan Levy, Katja Schulze, (unknown), Arisha Patel, Christopher J. Sweeney	32
6	Abstract LB012: Efficacy of atezolizumab in the treatment of solid tumors with high tumor mutational burden (TMB): A MyPathway study cohort 2021 ·Cancer Research ·John D. Hainsworth, Claire F. Friedman, Razelle Kurzrock, David R. Spigel, Howard A. Burris, Christopher J. Sweeney, Funda Meric‐Bernstam, Yong Wang, Jonathan Levy, David S. Shames, Katja Schulze, Arisha Patel, Charles Swanton	2
7	A study evaluating targeted therapies in participants who have advanced solid tumors with genomic alterations or protein expression patterns predictive of response (MyTACTIC). 2021 ·Journal of Clinical Oncology ·Axel Grothey, Michael F. Howland, (unknown), Tania Szado, (unknown), Walter C. Darbonne, Jonathan Levy, (unknown), David R. Spigel, Ari M. Vanderwalde, Lee S. Schwartzberg	1
8	Using Transportability to Understand Differences in Mediation Mechanisms Across Trial Sites of a Housing Voucher Experiment 2020 ·Epidemiology ·Kara E. Rudolph, Jonathan Levy, Nicole M. Schmidt, Elizabeth A. Stuart, Jennifer Ahern	8
9	Transporting stochastic direct and indirect effects to new populations 2020 ·Biometrics ·Kara E. Rudolph, Jonathan Levy, Mark J. van der Laan	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact